Evidence Review
Low Back Pain: Strongest Evidence
The best-designed trial of willow bark enrolled 210 patients with an acute exacerbation of chronic low back pain (pain ≥5/10 on a visual analogue scale) in a randomised, double-blind, placebo-controlled design over four weeks [1]. Participants received either high-dose extract (240 mg salicin/day), low-dose extract (120 mg salicin/day), or placebo.
In the final week of treatment, pain-free status was achieved in:
- 39% of the high-dose group (27/65 patients)
- 21% of the low-dose group (15/67 patients)
- 6% of the placebo group (4/59 patients)
The difference between high-dose and placebo was statistically significant (P <0.001), with a large effect size. The authors concluded that willow bark extract with 240 mg salicin was a meaningful short-term treatment for exacerbations of chronic low back pain. Adverse events were mild and primarily gastrointestinal, and less frequent than typically seen with NSAIDs.
A follow-up comparison trial tested willow bark against the synthetic anti-rheumatic rofecoxib (a COX-2 inhibitor later withdrawn from the market) in similar patients and found comparable efficacy, supporting willow bark as a legitimate pharmacological option rather than a placebo effect.
Musculoskeletal Pain: Systematic Review
A systematic review analysed seven manuscripts reporting four clinical trials of Salix preparations for musculoskeletal pain [2]. Three manuscripts reported overlapping data from the same trial and were excluded to avoid double-counting. The authors concluded there was moderate evidence supporting ethanolic willow bark extract for low back pain, with the strongest effect seen in the high-dose (240 mg salicin) groups. Evidence for other types of musculoskeletal pain — shoulder pain, neck pain — was insufficient to draw conclusions, largely due to lack of trials rather than negative results.
Arthritis: Meta-Analysis
A 2023 meta-analysis systematically searched PubMed, Scopus, EMBASE, Web of Science, and the Cochrane Register through April 2023 and identified five studies covering six randomised controlled trials involving 329 patients with arthritis [3]. The pooled analysis found statistically significant differences in pain relief and improvement in physical function scores between willow bark treatment groups and placebo. The authors noted that while the overall evidence is promising, individual trial quality was moderate and sample sizes were relatively small, calling for larger well-powered trials before definitive conclusions can be drawn.
Mechanistic studies explain why arthritis results are more mixed than the low back pain data: inflammatory arthritis involves multiple immune pathways (including 5-LOX and several cytokine cascades), and willow bark's primary salicylate pathway addresses only some of them. The polyphenol content contributes additional cytokine-suppressing effects, but the degree of this contribution varies by preparation.
Mechanisms and Synergy of Compounds
A laboratory study using established inflammation models in rats — both acute (6-day air pouch) and chronic (adjuvant-induced arthritis) — showed that standardised willow bark extract suppressed leukocytic infiltration, reduced levels of inflammatory prostaglandins and cytokines, and modestly inhibited both COX-1 and COX-2 activity [4]. Critically, this study found that the extract's effect was not fully explained by its salicylate content alone — the polyphenol fraction contributed independent anti-inflammatory activity. This provides mechanistic support for using standardised whole-bark extracts rather than isolated salicin.
Evidence Strength Summary
| Condition |
Evidence Level |
Notes |
| Low back pain (acute exacerbations) |
Moderate–Strong |
Multiple RCTs, consistent dose-response |
| Arthritis (general) |
Moderate |
Meta-analysis positive; individual RCT quality mixed |
| Neck/shoulder pain |
Insufficient |
No dedicated trials |
| Headache |
Anecdotal |
Historical use; no RCT evidence |
The overall picture is that willow bark is a reasonable evidence-based choice for low back pain in adults who prefer herbal approaches or want to reduce NSAID use, with a plausible but weaker case for arthritis support. It should not be used as a substitute for medical diagnosis or for conditions where NSAIDs are indicated urgently.